User profiles for S. Saraf

swarnlata Saraf

- Verified email at prsu.ac.in - Cited by 10189

Prof. Shailendra Saraf

- Verified email at prsu.ac.in - Cited by 9068

Sanatan Saraf

- Verified email at merck.com - Cited by 5530

Applications of novel drug delivery system for herbal formulations

S Saraf - Fitoterapia, 2010 - Elsevier
Over the past several years, great advances have been made on development of novel
drug delivery systems (NDDS) for plant actives and extracts. The variety of novel herbal …

Approaches for breaking the barriers of drug permeation through transdermal drug delivery

A Alexander, S Dwivedi, TK Giri, S Saraf, S Saraf… - Journal of controlled …, 2012 - Elsevier
Transdermal drug delivery system (TDDS) utilizes the skin as executable route for drug
administration but the foremost barrier against drug permeability is the stratum corneum and …

Nanocarriers: promising vehicle for bioactive drugs

M Rawat, D Singh, S Saraf, S Saraf - Biological and Pharmaceutical …, 2006 - jstage.jst.go.jp
… scale to nature such as biologicals like proteins, DNA and viruses, which are of the order
of 10’s of nanometers in size and cells and cellular assemblies of the order of 1000’s of …

Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs

M Agrawal, S Saraf, S Saraf, SG Antimisiaris… - Journal of controlled …, 2018 - Elsevier
… Author links open overlay panel Mukta Agrawal a , Swarnlata Saraf b , Shailendra Saraf
b c , Sophia G. Antimisiaris d e , Mahavir Bhupal Chougule f g h , Sunday A. Shoyele i , Amit …

Cyclodextrin based novel drug delivery systems

A Vyas, S Saraf, S Saraf - Journal of inclusion phenomena and …, 2008 - Springer
The versatile pharmaceutical material cyclodextrin’s (CDs) are classified into hydrophilic,
hydrophobic, and ionic derivatives. By the early 1950s the basic physicochemical …

Limonoids: overview of significant bioactive triterpenes distributed in plants kingdom

A Roy, S Saraf - Biological and Pharmaceutical Bulletin, 2006 - jstage.jst.go.jp
… (S)-… Stransferace and quinine reductase in the liver and mucosa of the small intestine to
detoxify chemical carcinogenesis. Studies show that the activity of phase II enzyme glutathione-S

Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study

…, A Algazi, EMJ Van Brummelen, S Saraf… - Journal of Clinical …, 2017 - ascopubs.org
Purpose To establish the safety profile and antitumor activity of the anti–programmed death
1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic …

4-Thiazolidinone–A biologically active scaffold

A Verma, SK Saraf - European journal of medicinal chemistry, 2008 - Elsevier
… Different derivatives of N-[3,4-disubstituted-1,3-thiazol-2(3H)-ylidene]-2-(pyrazin-2-yloxy)acetohydrazide
and N-[(2)-3-(4-alkyl/aryl substituted)-4-oxo-1,3-thiazolidin-2-ylidene]-2-(pyrazin-2-yloxy)acetohydrazide …

Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis

…, GY Perlman, OK Khalique, EW Holy, S Saraf… - Journal of the American …, 2017 - jacc.org
Background : Transcatheter aortic valve replacement (TAVR) is being increasingly performed
in patients with bicuspid aortic valve stenosis (AS). Objectives : This study sought to …

[PDF][PDF] Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028 trial

…, HS Rugo, S Thomas, S Saraf… - Journal of Clinical …, 2017 - clf1.medpagetoday.com
Purpose The KEYNOTE-028 trial (ClinicalTrials. gov identifier: NCT02054806) was designed
to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1–…